Inotiv Inc Stock Price, News & Analysis

Inotiv (NASDAQ: NOTV) will release fiscal 2025 fourth quarter and full year results for the period ended September 30, 2025 on Wednesday, December 3, 2025 after market close. Management will host a conference call the same day at 4:30 p.m. Eastern Time to discuss results.

Dial-in options include 1-800-225-9448 (Domestic) and 1-203-518-9708 (International) with conference ID INOTIV. A live webcast and an online replay will be available in the Investors section of the company website.

Inotiv (NASDAQ: NOTV) reported preliminary, unaudited Q4 FY2025 revenue of $137.5M–$138.5M and preliminary FY2025 revenue of $512.5M–$513.5M. Management said Discovery and Safety Assessment (DSA) services grew sequentially in Q4 and were up 60% year-over-year. Anticipated DSA backlog was approximately $138.0M at September 30, 2025, with book-to-bill ~1.08x for Q4 and ~1.05x for FY2025. Results are estimates and subject to year-end accounting and audit completion. The company updated its Jefferies Global Healthcare Conference presentation time to 11:00 AM GMT on Nov 18, 2025.

Inotiv (NASDAQ: NOTV) announced that management will participate in three investor conferences in November 2025: the UBS Global Healthcare Conference (Palm Beach Gardens, FL) on Nov 10–11, 2025 with 1-on-1 meetings; the Jefferies Global Healthcare Conference (London) on Nov 18, 2025 at 4:00 PM GMT / 11:00 AM ET with a presentation and 1-on-1 meetings (webcast link provided); and the Craig-Hallum Alpha Select Conference (New York) on Nov 18, 2025 with 1-on-1 meetings.

Company participants include Robert Leasure Jr., President & CEO, and Beth Taylor, CFO. Institutional investors should contact their sales representatives to schedule meetings.

Inotiv (NASDAQ:NOTV), a leading contract research organization focused on nonclinical drug discovery services and research models, announced its participation in three upcoming investor conferences in September 2025.

CEO Robert Leasure Jr. and CFO Beth Taylor will attend the H.C. Wainwright Global Investment Conference (September 10), the Baird Global Healthcare Conference (September 9), and the Lake Street Capital Markets Best Ideas Growth Conference (September 11). All events will take place in New York, NY, featuring presentations and one-on-one meetings with institutional investors.

Inotiv (NASDAQ:NOTV) reported strong Q3 FY2025 financial results with revenue increasing 23.5% to $130.7 million. The growth was driven by a 34.1% increase in Research Models & Services (RMS) revenue to $82.5 million and an 8.9% increase in Discovery & Safety Assessment (DSA) revenue to $48.2 million.

The company reduced its net loss to $17.6 million (13.5% of revenue) compared to $26.1 million in Q3 FY2024. Adjusted EBITDA improved significantly to $11.6 million (8.9% of revenue) from $0.1 million year-over-year. DSA backlog stood at $134.3 million with a book-to-bill ratio of 1.07x.

Notable developments include the SEC concluding its investigation related to non-human primate importations without recommending enforcement action, and a $10 million accrual for ongoing securities lawsuits, expected to be fully recovered through insurance.

Inotiv (NASDAQ:NOTV), a leading contract research organization, reported strong financial results for Q3 FY2025. Revenue increased 23.5% to $130.7 million, driven by significant growth in both Research Models & Services (RMS) and Discovery & Safety Assessment (DSA) segments.

The company reduced its net loss to $17.6 million (13.5% of revenue) from $26.1 million in Q3 FY2024. Adjusted EBITDA improved substantially to $11.6 million (8.9% of revenue) compared to $0.1 million last year. DSA segment showed strong momentum with a book-to-bill ratio of 1.07x and net awards increasing 25% year-over-year.

Notable developments include the SEC concluding its investigation related to non-human primate importations without recommending enforcement action, and a $10 million accrual for ongoing securities lawsuits, expected to be fully recovered through insurance.

Inotiv (NASDAQ:NOTV), a leading contract research organization focused on nonclinical and analytical drug discovery services, has scheduled its fiscal 2025 third quarter financial results announcement for August 6, 2025, after market close.

The company will host a conference call at 4:30 PM Eastern Time on the same day to discuss the results. Investors can access the call through domestic (1-800-245-3047) or international (1-203-518-9765) dial-in numbers using Conference ID: INOTIV. A live webcast will be available on the company's investor relations website, with a replay accessible afterward.

Inotiv (NASDAQ: NOTV), a contract research organization focused on nonclinical and analytical drug discovery and development services, has announced its participation in the upcoming Jefferies Global Healthcare Conference in New York. Robert Leasure Jr., President and CEO, will deliver a presentation on June 4 at 3:45 p.m. ET. The presentation will be available via live webcast through the company's investor relations website section and will remain accessible for approximately 90 days after the event.

Inotiv (NASDAQ: NOTV) reported mixed financial results for Q2 FY2025. Revenue increased 4.4% to $124.3 million in Q2, driven by a 9.1% growth in Research Models & Services (RMS) revenue, partially offset by a 2.8% decline in Discovery & Safety Assessment (DSA) revenue. However, year-to-date revenue declined 4.1% to $244.2 million. The company's net loss improved to $14.9 million (12% of revenue) compared to $48.1 million loss in Q2 FY2024. Adjusted EBITDA improved to $8.0 million (6.4% of revenue) from $3.1 million year-over-year. The company received a $7.6 million settlement payment from Freese and Nichols, Inc. DSA backlog stood at $130.8 million, down from $142.1 million year-over-year. The company continues to implement RMS site optimization plans in North America, expected to complete by Q2 FY2026, with two properties under contract for sale.